To date, immune targeting agents have provided limited benefits in patients with metastatic prostate cancer. Bispecific T-cell engagers, especially targeting STEAP1, have shown encouraging results in preclinical and phase I studies and thus represent a novel and promising treatment option in this setting. See related article by Nolan-Stevaux et al., p. 90 (7). See related article by Kelly et al., p. 76 (8).
Cancer discovery. 2024 Jan 12 [Epub]
Chadi Hage Chehade, Georges Gebrael, Neeraj Agarwal
Huntsman Cancer Institute, University of Utah (NCI-CCC), Salt Lake City, Utah.